Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home

PHASE3CompletedINTERVENTIONAL
Enrollment

162

Participants

Timeline

Start Date

April 27, 2015

Primary Completion Date

March 14, 2016

Study Completion Date

March 14, 2016

Conditions
Asthma
Interventions
BIOLOGICAL

Benralizumab

Benralizumab administered subcutaneously every 4 weeks

Trial Locations (23)

Unknown

Research Site, Fountain Valley

Research Site, Walnut Creek

Research Site, Celebration

Research Site, Ocala

Research Site, Orlando

Research Site, Winter Park

Research Site, Albany

Research Site, Minneapolis

Research Site, St Louis

Research Site, Bellevue

Research Site, Oklahoma City

Research Site, San Antonio

Research Site, Calgary

Research Site, Vancouver

Research Site, Ajax

Research Site, Burlington

Research Site, Mississauga

Research Site, Toronto

Research Site, Montreal

Research Site, Pointe-Claire

Research Site, Québec

Research Site, Saint-Charles-Borromée

Research Site, Trois-Rivières

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY